finance

Barclays downgrades Reata Pharma to 'equalweight' with a price target of $172.00




Barclays downgrades Reata Pharma to 'equalweight' with a price target of $172.00



READ SOURCE

Readers Also Like:  North Sea output to halve by 2030 under Labour tax proposals, warns report

This website uses cookies. By continuing to use this site, you accept our use of cookies.